Eleazar Enrique Montalvan-Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eleazar Enrique Montalvan-Sanchez has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Dalton Argean Norwood
Division of General Internal Medicine, University of Alabama at Birmingham , Birmingham, AL
50 shared publications - Douglas R. Morgan
Division of Gastroenterology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
45 shared publications - Ricardo L. Dominguez
Western Honduras Gastric Cancer Program, Ministry of Health, Santa Rosa de Copan, Honduras
37 shared publications - Aida Rodriguez-Murillo
Department of Medicine, University of Nevada Reno , Reno, NV
32 shared publications - Timothy Beasley
Department of Biostatistics, School of Public Health, The University of Alabama at Birmingham, Birmingham, Alabama
31 shared publications - Jessica Hernandez-Marrero
University of Puerto Rico, San Juan, Puerto Rico
25 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Clinical characteristics and phenotypes of inflammatory bowel disease in Northern Central America: initial results from the Northern Central America Inflammatory Bowel Disease Registry
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC), Crohn’s disease (CD), and IBD unclassified (IBDU), affects over 7 million people worldwide. While incidence has plateaued in higher-income countries, it continues to rise in lower- and middle-income regions, including Latin America. Data from northern Central America remain scarce. Aim: To characterize the clinical and phenotypic profile of IBD in Honduras, El Salvador, and Guatemala. Methods: The Inflammatory Bowel Disease in Northern Central America Research and Epidemiological Study (IBD-NCARES) was a multinational, multicenter descriptive study spanning 15 years. Cases were identified using ICD-10 codes and confirmed by chart review. Sociodemographic, behavioral, and clinical variables were collected. Results: Among 277 patients, UC was the predominant subtype (57.8%), highest in Honduras (71.4%). CD accounted for 11.9% of cases, with greater frequency in Honduras (25.7%). IBDU was frequent in El Salvador (40.3%) and Guatemala (38.2%) compared with Honduras (2.9%). Delayed diagnosis (>1 year) occurred in 35% of UC and 60.6% of CD patients. Complicated CD was observed in 54.5% (B2 30.3%; B3 24.2%). Extraintestinal manifestations included vascular (18.2%) and hepatic/pancreatic (9.1%) complications. Most patients received 5-aminosalicylates or systemic steroids. Only 5.1% of the overall cohort received advanced therapies. Conclusion: This first multinational study of IBD in northern Central America highlights UC predominance, high rates of IBDU (likely inflated by incomplete diagnostics), frequent diagnostic delay, and limited use of advanced therapies. These findings underscore the need for regional registries, improved diagnostic capacity, and expanded therapeutic resources.
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Open AccessClinical characteristics and phenotypes of inflammatory bowel disease in Northern Central America: initial results from the Northern Central America Inflammatory Bowel Disease Registry
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC), Crohn’s disease (CD), and IBD unclassified (IBDU), affects over 7 million people worldwide. While incidence has plateaued in higher-income countries, it continues to rise in lower- and middle-income regions, including Latin America. Data from northern Central America remain scarce. Aim: To characterize the clinical and phenotypic profile of IBD in Honduras, El Salvador, and Guatemala. Methods: The Inflammatory Bowel Disease in Northern Central America Research and Epidemiological Study (IBD-NCARES) was a multinational, multicenter descriptive study spanning 15 years. Cases were identified using ICD-10 codes and confirmed by chart review. Sociodemographic, behavioral, and clinical variables were collected. Results: Among 277 patients, UC was the predominant subtype (57.8%), highest in Honduras (71.4%). CD accounted for 11.9% of cases, with greater frequency in Honduras (25.7%). IBDU was frequent in El Salvador (40.3%) and Guatemala (38.2%) compared with Honduras (2.9%). Delayed diagnosis (>1 year) occurred in 35% of UC and 60.6% of CD patients. Complicated CD was observed in 54.5% (B2 30.3%; B3 24.2%). Extraintestinal manifestations included vascular (18.2%) and hepatic/pancreatic (9.1%) complications. Most patients received 5-aminosalicylates or systemic steroids. Only 5.1% of the overall cohort received advanced therapies. Conclusion: This first multinational study of IBD in northern Central America highlights UC predominance, high rates of IBDU (likely inflated by incomplete diagnostics), frequent diagnostic delay, and limited use of advanced therapies. These findings underscore the need for regional registries, improved diagnostic capacity, and expanded therapeutic resources.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S9 presents laboratory test abnormalities reported as adverse events, including specific analytes and event resolution by treatment arm.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Table S9 presents laboratory test abnormalities reported as adverse events, including specific analytes and event resolution by treatment arm.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S4. Representativeness of Study Participants.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S4. Representativeness of Study Participants.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S1 shows boxplots of gastric mucosal IL-1β concentrations at baseline, 6 months, and the change from baseline to 6 months, stratified by treatment arm (placebo vs. curcumin), including both gastric antrum and corpus samples.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S1 shows boxplots of gastric mucosal IL-1β concentrations at baseline, 6 months, and the change from baseline to 6 months, stratified by treatment arm (placebo vs. curcumin), including both gastric antrum and corpus samples.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Gastric adenocarcinoma is the fifth leading cause of global cancer mortality and a major health disparity in the United States. Effective chemoprevention strategies are limited for high-risk individuals with gastric premalignant conditions (GPMC). We conducted an NCI Division of Cancer Prevention–funded, double-blinded, phase IIa randomized, placebo-controlled trial evaluating eflornithine for chemoprevention in GPMC (NCT02794428). The study was executed in rural Honduras and Puerto Rico, regions with a high prevalence of Helicobacter pylori and gastric intestinal metaplasia (GIM), from September 2016 to December 2022. Eligible subjects (ages 30–69; H. pylori–positive or H. pylori–negative) were randomized 1:1 to receive 500 mg/day eflornithine or placebo for 18 months. Upper endoscopy was performed at baseline, 6, 18, and 24 months. H. pylori–positive patients were offered antibiotic treatment at 6 months. A total of 211 patients were screened, and 91 were randomized (45 to eflornithine and 46 to placebo). The mean age was 45.2 years (SD 8.8), and 74% were female. At baseline, 46% and 54% had gastric atrophy and GIM, respectively. Eighty percent were H. pylori–positive. Follow-up completion rates were 78 patients (6 months), 69 patients (18 months), and 55 patients (24 months). Eflornithine was well tolerated, with fewer grade 1 to 2 adverse events in the eflornithine group (81 vs. 108, placebo). No significant histology score differences were observed. A significant reduction in DNA damage (pH2AX-positive cells) was observed in the 24-month versus 18-month assessments (P = 0.012). Eflornithine was safe and well tolerated in patients with GPMC. The findings suggest that eflornithine reduces long-term DNA damage, supporting further trials to refine treatment duration and patient selection.Prevention Relevance:Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation—alone or combined with H. pylori eradication—as a strategy to interrupt gastric carcinogenesis in high-risk populations.See related Spotlight, p. 387See related article by Gonzalez-Pons et al., p. 403
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Gastric adenocarcinoma is the fifth leading cause of global cancer mortality and a major health disparity in the United States. Effective chemoprevention strategies are limited for high-risk individuals with gastric premalignant conditions (GPMC). We conducted an NCI Division of Cancer Prevention–funded, double-blinded, phase IIa randomized, placebo-controlled trial evaluating eflornithine for chemoprevention in GPMC (NCT02794428). The study was executed in rural Honduras and Puerto Rico, regions with a high prevalence of Helicobacter pylori and gastric intestinal metaplasia (GIM), from September 2016 to December 2022. Eligible subjects (ages 30–69; H. pylori–positive or H. pylori–negative) were randomized 1:1 to receive 500 mg/day eflornithine or placebo for 18 months. Upper endoscopy was performed at baseline, 6, 18, and 24 months. H. pylori–positive patients were offered antibiotic treatment at 6 months. A total of 211 patients were screened, and 91 were randomized (45 to eflornithine and 46 to placebo). The mean age was 45.2 years (SD 8.8), and 74% were female. At baseline, 46% and 54% had gastric atrophy and GIM, respectively. Eighty percent were H. pylori–positive. Follow-up completion rates were 78 patients (6 months), 69 patients (18 months), and 55 patients (24 months). Eflornithine was well tolerated, with fewer grade 1 to 2 adverse events in the eflornithine group (81 vs. 108, placebo). No significant histology score differences were observed. A significant reduction in DNA damage (pH2AX-positive cells) was observed in the 24-month versus 18-month assessments (P = 0.012). Eflornithine was safe and well tolerated in patients with GPMC. The findings suggest that eflornithine reduces long-term DNA damage, supporting further trials to refine treatment duration and patient selection.Prevention Relevance:Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation—alone or combined with H. pylori eradication—as a strategy to interrupt gastric carcinogenesis in high-risk populations.See related Spotlight, p. 387See related article by Gonzalez-Pons et al., p. 403
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori.Prevention Relevance:Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction.See related Spotlight, p. 387See related article by Morgan et al., p. 391
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori.Prevention Relevance:Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction.See related Spotlight, p. 387See related article by Morgan et al., p. 391
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Figure S1 shows the absolute mean pH2AX immunohistochemistry scores (± standard error) at baseline, 6, 18, and 24 months for participants randomized to eflornithine or placebo. No statistically significant differences between groups were observed at any individual time point.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial
Supplementary Figure S1 shows the absolute mean pH2AX immunohistochemistry scores (± standard error) at baseline, 6, 18, and 24 months for participants randomized to eflornithine or placebo. No statistically significant differences between groups were observed at any individual time point.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S2 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) at baseline, 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S2 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) at baseline, 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S1 provides the completed CONSORT 2010 checklist summarizing trial design, methodology, reporting elements, and corresponding manuscript page numbers.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S1 provides the completed CONSORT 2010 checklist summarizing trial design, methodology, reporting elements, and corresponding manuscript page numbers.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S3 presents summary statistics for gastric mucosal cytokine and chemokine concentrations (IL-1β, IL-8, TNFα, IP-10) at baseline and 6 months by treatment arm, including measures of central tendency, dispersion, and nonparametric between-group comparisons.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S3 presents summary statistics for gastric mucosal cytokine and chemokine concentrations (IL-1β, IL-8, TNFα, IP-10) at baseline and 6 months by treatment arm, including measures of central tendency, dispersion, and nonparametric between-group comparisons.